Drug Profile

REC 604a

Alternative Names: REC-604a

Latest Information Update: 02 Nov 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Jiangsu Recbio Technology
Class Antineoplastics; Cancer vaccines; Immunotherapies; Papillomavirus vaccines; Virus-like particle vaccines
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Preclinical Cervical cancer; Genital warts

Most Recent Events

27 Oct 2022 Jiangsu Recbio Technology receives a notice of acceptance from the NMPA to accept the application for a clinical trial of REC 604a
27 Oct 2022 Pharmacodynamics data from a preclinical study released by Jiangsu Recbio Technology
28 Aug 2022 Jiangsu Recbio Technology plans to submit IND application to NMPA in China, in the second half of 2022

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com